The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BMRA | -48.1% | -96.61% | -49.18% | -98% |
| S&P | +15.58% | +78.13% | +12.24% | +4,179% |
Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The firm focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, United States, Asia, South America, Middle East, and Other. The company was founded in September 1971 and is headquartered in Irvine, CA.
No news articles found for Biomerica.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.21M | -26.0% |
| Gross Profit | $51.00K | -88.3% |
| Gross Margin | 4.21% | -22.5% |
| Market Cap | $6.80M | 3.8% |
| Market Cap / Employee | $125.96K | 0.0% |
| Employees | 54 | -15.6% |
| Net Income | -$1,320.00K | -38.9% |
| EBITDA | -$1,270.00K | -42.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $2.54M | 7.2% |
| Accounts Receivable | $947.00K | -28.6% |
| Inventory | 1.5 | -14.8% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | -100.0% |
| Short Term Debt | $284.00K | -17.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -60.49% | -1.8% |
| Return On Invested Capital | -75.86% | -20.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$991.00K | -25.3% |
| Operating Free Cash Flow | -$991.00K | -25.3% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.70 | 1.40 | 1.44 | 1.29 | 5.61% |
| Price to Sales | 2.48 | 1.46 | 1.69 | 1.55 | 29.27% |
| Price to Tangible Book Value | 22.10 | 1.47 | 1.50 | 1.35 | -86.74% |
| Enterprise Value to EBITDA | -10.43 | -3.99 | -5.49 | -3.65 | -33.82% |
| Return on Equity | -72.7% | -93.0% | -69.6% | -84.3% | 9.02% |
| Total Debt | $543.00K | $458.00K | $373.00K | $284.00K | -54.63% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
